From November 13th to 15th, 2024, the "16th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference," hosted by the China Pharmaceutical Enterprise Management Association, China Pharmaceutical Biotechnology Association, and Sichuan Pharmaceutical Industry Association, was held in Chengdu. During the conference, the "2024 Top 100 Chinese Pharmaceutical Innovative Enterprises" and "2024 Top 5 Chinese Pharmaceutical Innovative Enterprises in the Technology Category" lists were ceremoniously released. With its outstanding performance in innovative biopharmaceuticals, Biokin Pharmaceutical has made the first-tier top ten group of the "Top 100 Chinese Pharmaceutical Innovative Enterprises" list and won the title of "Top 5 Chinese Pharmaceutical Innovative Enterprises in the ADC Category".

This list is one of the most credible and influential pharmaceutical innovation lists in the pharmaceutical innovation and investment fields. Compiled by E-Pharma Manager based on Clarivate's Derwent Innovation™ patent data and Cortellis™ competitive intelligence and clinical trial data, the list was selected after months of data screening, integration, and analysis using a "three dimensions and four indicators" evaluation system.

As the first tier representing China's pharmaceutical innovation capability, the "Top 100 Chinese Pharmaceutical Innovative Enterprises" series of lists is the main force driving the transformation and upgrading of China's pharmaceutical industry and building industry competitiveness. It also provides experience and benchmarks for those who follow.